Saving changes...

Done

Error

2018 ACCP Journal of Clinical Pharmacology Journal CE December | Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

2018 ACCP Journal of Clinical Pharmacology Journal CE December | Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

2018 ACCP Journal of Clinical Pharmacology Journal CE December | Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Xianbin Tian (PhD), Hefei Zhang (MD, PhD), Tycho Heimbach (PhD), Handan He (PhD), Aby Buchbinder (MD
Xianbin Tian (PhD), Hefei Zhang (MD, PhD), Tycho Heimbach (PhD), Handan He (PhD), Aby Buchbinder (MD
on behalf of American College of Clinical Pharmacology

$10.00 $ 10.00 $ 10.00

$10.00 $ 10.00 $ 10.00

$ 10.00 $ 10.00 $ 10.00
$ 10.00 $ 10.00 $ 10.00
Normal Price: $10.00 $10.00

Review:

Launch date: 10 Dec 2018
Expiry Date: 31 Dec 2020

Last updated: 18 Dec 2018

Reference: 193009

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Learners that complete this course will be able to summarize the pharmacokinetic and pharmacodynamic properties of nilotinib, a second-generation tyrosine kinase inhibitor, including its drug-drug and food-drug interactions, exposure-efficacy and exposure-safety relationships when used in the treatment of newly diagnosed chronic myeloid leukemia (CML) or accelerated phase CML resistant or intolerant to prior therapy. Clinicians will be able to describe how the PK and PD profiles of nilotinib inform tailoring of treatment to individual patients.

Objectives

Identify nilotinib-eligible oncology conditions including individualized dosage adjustments based upon patient-specific conditions
After completing this activity, the learner will be able to identify nilotinib-eligible oncology conditions including individualized dosage adjustments based upon patient-specific conditions.
Verbalize the rationale and importance of adhering to nilotinib administration 2 hours before or 1 hour after food to achieve predictable drug serum concentrations
After completing this activity, the learner will be able to verbalize the rationale and importance of adhering to nilotinib administration 2 hours before or 1 hour after food to achieve predictable drug serum concentrations.
Discuss the exposure-safety of nilotinib on QT prolongation and implications for dosing, monitoring and avoidance of concomitant use of QT-prolonging drugs
After completing this activity, the learner will be able to discuss the exposure-safety of nilotinib on QT prolongation and implications for dosing, monitoring and avoidance of concomitant use of QT-prolonging drugs.
Identify the impact of gastric pH on the absorption of nilotinib and how to minimize the impact of gastric acid neutralizing agents
After completing this activity, the learner will be able to identify the impact of gastric pH on the absorption of nilotinib and how to minimize the impact of gastric acid neutralizing agents.
Xianbin Tian (PhD), Hefei Zhang (MD, PhD), Tycho Heimbach (PhD), Handan He (PhD), Aby Buchbinder (MD

Author Information Play Video Bio

Xianbin Tian (PhD), Hefei Zhang (MD, PhD), Tycho Heimbach (PhD), Handan He (PhD), Aby Buchbinder (MD
on behalf of American College of Clinical Pharmacology

In the 1960s, a group of eminent physicians formulated the concept of an organization dedicated to a new branch of pharmacology that dealt with the effectiveness and safety of drugs in man. As a result of their efforts, the American College of Clinical Pharmacology (ACCP) was founded on September 11, 1969. Today, ACCP consists of a full spectrum of clinical pharmacology professionals from academia, industry, government and clinical settings who span the scope from research and drug development to patient-related care and who remain dedicated to advancing clinical pharmacology with the ultimate goal of enhancing patient care.

As an organization whose primary role is education, ACCP does not concentrate on any one aspect of the discipline. Rather, it seeks to address the educational needs of its diverse membership and all healthcare professionals, covering a range of topics that span the entire area of the interaction between drugs and humans. These areas include, but are not limited to, pharmaceutical chemistry, biochemistry, drug metabolism, pharmacokinetics, pharmacodynamics, pharmacometrics, pharmacogenomics clinical pharmacology practice in the outpatient and inpatient settings, human toxicology, drug interactions and clinical drug trials. The diversity of ACCP is expressed not only in the composition of its membership, but also in its leadership. Maintaining a balance of elected Regents and Officers from all pertinent professional backgrounds ensures that ACCP remains attuned to the needs of all professionals engaged in the practice of or with a strong interest in clinical pharmacology, from the research laboratory (academic and industrial) to the classroom, and from clinical trials to improved patient care.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.00 Credits
  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.00 Hours -
    Exam Pass Rate: 75

Faculty and Disclosures

Joseph Bertino,  PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc

Joseph Bertino, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc

Selected the article for this course and has nothing to disclose.
Sandeep Kaushal, MBBS, MD, FCP, Professor & Head of Pharmacology, Dayanand Medical Coll & Hospital

Sandeep Kaushal, MBBS, MD, FCP, Professor & Head of Pharmacology, Dayanand Medical Coll & Hospital

Planned the continuing education documentation for this course and has nothing to disclose.
Hisham Qosa,  PhD, Clinical Pharmacologist, US Food & Drug Admin, Office of Clinical Pharmacology – Division V

Hisham Qosa, PhD, Clinical Pharmacologist, US Food & Drug Admin, Office of Clinical Pharmacology – Division V

Has nothing to disclose.

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error